

16 October 2025

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Fundraise & Transaction Update

Roquefort Therapeutics plc ([LSE:ROQ](#)), the Main Market listed biotech company, is pleased to announce that it has raised funds of £300,000, with £200,000 by way of advance subscription agreements ("Advance Subscriptions") from certain strategic investors, and £100,000 by way of a loan from A2A Pharmaceuticals, Inc. ("A2A Pharma") (the "A2A Pharma Loan").

The aggregate net proceeds of the Advance Subscriptions and A2A Pharma Loan will be used to fund the upfront costs of the proposed transaction with A2A Pharma and Coiled Therapeutics, Inc. ("Coiled USA") which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the "Proposed Transaction"), initially announced by the Company on 8 September 2025.

Stephen West, the Company's Chairman, participated in the Advance Subscriptions with an investment of £45,000.

Terms of the Advance Subscriptions

The Advance Subscriptions instrument allows investors to subscribe for ordinary shares in the Company at a discount of 20% to the issue price at the next placing ("Next Placing Price") undertaken by the Company in conjunction with the Proposed Transaction. The determination of the issue price and the issue of the Advance Subscriptions shares will take place in conjunction with completion of the Proposed Transaction. The Advance Subscriptions instrument includes a right to receive a one for one warrant in the event that the Advance Subscription shares are still held by the investor on 30 June 2026 ("Loyalty Warrant"). The Loyalty Warrant has an exercise price equal to the Next Placing Price and a term of two years from the issue date.

Terms of the A2A Pharma Loan

The A2A Pharma Loan accrues interest at a rate of 5% and is repayable on the earlier of (a) the date of completion of the Proposed Transaction; (b) the date falling 12 months after the loan; or (c) the date falling 6 months after the term sheet relating to the Proposed Transaction is terminated.

A2A Pharma may, at its sole discretion, elect to convert some or all of the A2A Pharma Loan into ordinary shares in Roquefort Therapeutics at a price of 2p per share.

Proposed Transaction Update

The Company has appointed all the advisors required to complete the documentation for the Proposed Transaction and drafting of the main transaction documents is now progressing well. The Company will provide further updates on the Proposed Transaction in due course.

Stephen West, Executive Chairman, commented:

"We are pleased to have completed this fundraise which provides the funding for the upfront costs associated with our recently announced proposed value accretive transaction. It is particularly pleasing to see the participation of A2A Pharma for a significant amount of the proceeds raised, demonstrating their commitment to move the deal towards completion in an efficient and timely manner. We look forward to providing more updates as appropriate as we hit the critical milestones of this transformative transaction."

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman) / Dr Darrin Disley (Interim MD)

+44 (0)20 3918 8633

SP Angel Corporate Finance LLP (Broker to the Company)

David Hignell / Vadim Alexandre / Devik Mehta

+44 (0)20 3470 0470

CPS Capital (Broker to A2A Pharmaceuticals & Coiled USA)

Jason Peterson / David Valentino

+61 (0)8 9223 2222

Burson Buchanan (Public Relations)

Ben Romney / Jamie Hooper

+44 (0)20 7466 5000

LEI: 254900P4SISIWOR9RH34

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

About Coiled USA

Coiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. ("A2A Pharma"). Coiled USA, in conjunction with A2A Pharma, holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions. Coiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.

About A2A Pharma

A2A Pharma is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT™ platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.

A2A Pharma aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development. In 2018 A2A Pharma spun out its MLL-Menin program to Biomea Fusion, Inc. ("Biomea Fusion"), a company that completed an IPO on Nasdaq in 2021 raising US 153 million and listing with a market capitalisation of US 464 million. Post-IPO, Biomea Fusion's market capitalisation reached a peak of over US 1 billion.

Further information on A2A Pharmaceuticals can be found at: <https://www.a2apharma.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEMABBTMTIBBPA